Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety and Translational Proof of Mechanism in RENOIR, a Phase 2B Trial in Moderate-to-Severe Rheumatoid Arthritis